I. Nicol Ferrier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
I. Nicol Ferrier has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Adrian J. Lloyd
Clinical Research Associate, Wolfson Research Centre, Newcastle General Hospital, Newcastle NE4 6BE, UK
2 shared publications - Allan Hunter Young
Imperial College London
2 shared publications Jill M. Thompson
Institute of Neuroscience (Academic Psychiatry), Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle General Hospital, Newcastle upon Tyne, NE4 5PL, UK
2 shared publications- Peter Gallagher
Newcastle University
2 shared publications - Allan House
University of Leeds
1 shared publication - Allan Hunter Young
School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, UK
1 shared publication
Latest Publications
- 21 January 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 228 (2) , 180-181
Psychological Classification and Diagnosis in Asylum Statistics, 1800–1948: The British Table of the Forms of Insanity By Kevin Matthew Jones. Palgrave Macmillan. March 2025. £109.99 (hb). 355 pp. ISBN 978-3031461538
- 21 January 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 228 (2) , 180-181
Psychological Classification and Diagnosis in Asylum Statistics, 1800–1948: The British Table of the Forms of Insanity By Kevin Matthew Jones. Palgrave Macmillan. March 2025. £109.99 (hb). 355 pp. ISBN 978-3031461538
- Open Access
- 8 October 2024
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 32 (1) , 57-59
Lunatic Asylums: Their Organisation and Management , by Charles Arthur Mercier
SUMMARY: Lunatic Asylums , published 130 years ago, is a fascinating insight into how these institutions were managed in the late Victorian era. This brief article considers what it reveals about the zeitgeist of the time and the book's author, the remarkable Charles Mercier.
- 8 October 2024
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 32 (1) , 57-59
Open AccessLunatic Asylums: Their Organisation and Management , by Charles Arthur Mercier
SUMMARY: Lunatic Asylums , published 130 years ago, is a fascinating insight into how these institutions were managed in the late Victorian era. This brief article considers what it reveals about the zeitgeist of the time and the book's author, the remarkable Charles Mercier.
- Open Access
- 9 March 2021
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 27 (5) , 295-302
Recent advances in electroconvulsive therapy and physical treatments for depression
SUMMARY: This article gives an update for practitioners on recent developments in the use of electroconvulsive therapy (ECT) and related treatment modalities in the contemporary treatment of depression in the UK. Details are provided on new information on the efficacy and side-effects of ECT both in research studies and in the real world, together with recent research on ECT's mode of delivery. There is a focus on the safe administration of ECT in clinical practice. An update on the regulatory framework for ECT in the UK is provided, together with up-to-date information on the legal situation regarding its prescription. Finally, brief summaries of the current position for other neuromodulatory treatment modalities are given.
- 9 March 2021
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 27 (5) , 295-302
Open AccessRecent advances in electroconvulsive therapy and physical treatments for depression
SUMMARY: This article gives an update for practitioners on recent developments in the use of electroconvulsive therapy (ECT) and related treatment modalities in the contemporary treatment of depression in the UK. Details are provided on new information on the efficacy and side-effects of ECT both in research studies and in the real world, together with recent research on ECT's mode of delivery. There is a focus on the safe administration of ECT in clinical practice. An update on the regulatory framework for ECT in the UK is provided, together with up-to-date information on the legal situation regarding its prescription. Finally, brief summaries of the current position for other neuromodulatory treatment modalities are given.
- Open Access
- 3 August 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 205
Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)
Some patients with depression do not respond to first and second line conventional antidepressants and are therefore characterised as suffering from treatment refractory depression (TRD). On-going psychosocial stress and dysfunction of the hypothalamic-pituitary-adrenal axis are both associated with an attenuated clinical response to antidepressants. Preclinical data shows that co-administration of corticosteroids leads to a reduction in the ability of selective serotonin reuptake inhibitors to increase forebrain 5-hydroxytryptamine, while co-administration of antiglucocorticoids has the opposite effect. A Cochrane review suggests that antiglucocorticoid augmentation of antidepressants may be effective in treating TRD and includes a pilot study of the cortisol synthesis inhibitor, metyrapone. The Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study) is a multicentre randomised placebo controlled trial of metyrapone augmentation of serotonergic antidepressants in a large population of patients with TRD in the UK National Health Service. Patients with moderate to severe treatment refractory Major Depression aged 18 to 65 will be randomised to metyrapone 500 mg twice daily or placebo for three weeks, in addition to on-going conventional serotonergic antidepressants. The primary outcome will be improvement in Montgomery-Åsberg Depression Rating Scale score five weeks after randomisation (i.e. two weeks after trial medication discontinuation). Secondary outcomes will include the degree of persistence of treatment effect for up to 6 months, improvements in quality of life and also safety and tolerability of metyrapone. The ADD Study will also include a range of sub-studies investigating the potential mechanism of action of metyrapone. Strengths of the ADD study include broad inclusion criteria meaning that the sample will be representative of patients with TRD treated within the UK National Health Service, longer follow up, which to our knowledge is longer than any previous study of antiglucocorticoid treatments in depression, and the range of mechanistic investigations being carried out. The data set acquired will be a rich resource for a range of research questions relating to both refractory depression and the use of antiglucocorticoid treatments. Current Controlled Trials: ISRCTN45338259 ; EudraCT Number: 2009-015165-31.
- 3 August 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 205
Open AccessStudy protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)
Some patients with depression do not respond to first and second line conventional antidepressants and are therefore characterised as suffering from treatment refractory depression (TRD). On-going psychosocial stress and dysfunction of the hypothalamic-pituitary-adrenal axis are both associated with an attenuated clinical response to antidepressants. Preclinical data shows that co-administration of corticosteroids leads to a reduction in the ability of selective serotonin reuptake inhibitors to increase forebrain 5-hydroxytryptamine, while co-administration of antiglucocorticoids has the opposite effect. A Cochrane review suggests that antiglucocorticoid augmentation of antidepressants may be effective in treating TRD and includes a pilot study of the cortisol synthesis inhibitor, metyrapone. The Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study) is a multicentre randomised placebo controlled trial of metyrapone augmentation of serotonergic antidepressants in a large population of patients with TRD in the UK National Health Service. Patients with moderate to severe treatment refractory Major Depression aged 18 to 65 will be randomised to metyrapone 500 mg twice daily or placebo for three weeks, in addition to on-going conventional serotonergic antidepressants. The primary outcome will be improvement in Montgomery-Åsberg Depression Rating Scale score five weeks after randomisation (i.e. two weeks after trial medication discontinuation). Secondary outcomes will include the degree of persistence of treatment effect for up to 6 months, improvements in quality of life and also safety and tolerability of metyrapone. The ADD Study will also include a range of sub-studies investigating the potential mechanism of action of metyrapone. Strengths of the ADD study include broad inclusion criteria meaning that the sample will be representative of patients with TRD treated within the UK National Health Service, longer follow up, which to our knowledge is longer than any previous study of antiglucocorticoid treatments in depression, and the range of mechanistic investigations being carried out. The data set acquired will be a rich resource for a range of research questions relating to both refractory depression and the use of antiglucocorticoid treatments. Current Controlled Trials: ISRCTN45338259 ; EudraCT Number: 2009-015165-31.
- 20 July 2013
- Published by Elsevier in Psychiatry Research
- Vol. 210 (2) , 457-464
Performance monitoring and executive control of attention in euthymic bipolar disorder: Employing the CPT-AX paradigm
- 20 July 2013
- Published by Elsevier in Psychiatry Research
- Vol. 210 (2) , 457-464
Performance monitoring and executive control of attention in euthymic bipolar disorder: Employing the CPT-AX paradigm
- Open Access
- 8 April 2010
- Published by Taylor & Francis in Journal of Mental Health
- Vol. 19 (2) , 111-112
Special Issue on Bipolar Disorder
(2010). Special Issue on Bipolar Disorder. Journal of Mental Health: Vol. 19, No. 2, pp. 111-112. doi: 10.3109/09638231003610984
- 8 April 2010
- Published by Taylor & Francis in Journal of Mental Health
- Vol. 19 (2) , 111-112
Open AccessSpecial Issue on Bipolar Disorder
(2010). Special Issue on Bipolar Disorder. Journal of Mental Health: Vol. 19, No. 2, pp. 111-112. doi: 10.3109/09638231003610984
- 29 February 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 98, 18
Diffusion tensor MRI abnormalities of hemispheric and callosal white matter in euthymic bipolar subjects with executive dysfunction
- 29 February 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 98, 18
Diffusion tensor MRI abnormalities of hemispheric and callosal white matter in euthymic bipolar subjects with executive dysfunction
- Open Access
- 1 April 2002
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 180 (4) , 293-295
Cognitive impairment in bipolar affective disorder: implications for the bipolar diathesis
- 1 April 2002
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 180 (4) , 293-295
Open AccessCognitive impairment in bipolar affective disorder: implications for the bipolar diathesis
- Open Access
- 1 June 2001
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 178 (S41) , s103-s106
The search for the wandering thymostat: a review of some developments in bipolar disorder research
- 1 June 2001
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 178 (S41) , s103-s106
Open AccessThe search for the wandering thymostat: a review of some developments in bipolar disorder research
- 1 April 2001
- Published by Wiley in Bipolar Disorders
- Vol. 3 (2) , 79-87
Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder
Objectives: EEG abnormalities and neurocognitive deficits have been reported in patients with bipolar affective disorder. The aim of this study was to ascertain whether brain function remains impaired in young bipolar patients who have become euthymic in response to treatment. Methods: Brain function was assessed by quantitative electroencephalographic (EEG) power‐spectral mapping and by a battery of neuropsychological tests. The subjects were 29 euthymic bipolar patients aged 18–40 years and 26 healthy volunteers of similar age, IQ and socioeconomic status. Results: Grand means of spectral power of the resting EEG showed significantly (from pConclusions: The findings show significant disturbance of EEG activity and deficits in visuospatial processing in young bipolar patients despite clinical euthymia. The abnormalities were not related to age of onset or duration of illness and do not appear to be attributable to medication. The cognitive impairments were associated with the number of previous affective episodes.
- 1 April 2001
- Published by Wiley in Bipolar Disorders
- Vol. 3 (2) , 79-87
Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder
Objectives: EEG abnormalities and neurocognitive deficits have been reported in patients with bipolar affective disorder. The aim of this study was to ascertain whether brain function remains impaired in young bipolar patients who have become euthymic in response to treatment. Methods: Brain function was assessed by quantitative electroencephalographic (EEG) power‐spectral mapping and by a battery of neuropsychological tests. The subjects were 29 euthymic bipolar patients aged 18–40 years and 26 healthy volunteers of similar age, IQ and socioeconomic status. Results: Grand means of spectral power of the resting EEG showed significantly (from pConclusions: The findings show significant disturbance of EEG activity and deficits in visuospatial processing in young bipolar patients despite clinical euthymia. The abnormalities were not related to age of onset or duration of illness and do not appear to be attributable to medication. The cognitive impairments were associated with the number of previous affective episodes.